https://openbell.ai/ 2026-10-26T07:40:48.735Z hourly 1.0 https://openbell.ai/support 2026-10-26T07:40:48.735Z monthly 0.7 https://openbell.ai/privacy 2026-10-26T07:40:48.735Z monthly 0.5 https://openbell.ai/terms 2026-10-26T07:40:48.735Z monthly 0.5 https://openbell.ai/feed.json 2026-10-26T07:40:48.735Z hourly 0.8 https://openbell.ai/news/CCC:1792999899000 2026-10-26T07:31:39.000Z daily 0.9 https://cdn.brandfetch.io/CCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Computacenter plc Announces Q3 Trading Update and Upward Guidance Revision Computacenter plc reported Q3 performance above internal and market expectations, citing strong operational results. It raised its full-year 2026 adjusted profit-before-tax outlook to at least £425 million, up from analyst consensus of £387.1 million. https://openbell.ai/news/AGEN:1792976627000 2026-10-26T01:03:47.000Z daily 0.9 https://cdn.brandfetch.io/AGEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Agenus Reports Positive Phase 2 Results for BOT+BAL in NEOASIS Study at ESMO 2026 Agenus reported early Phase 2 results from the NEOASIS study showing that 72% of patients with locally advanced dMMR colon cancer had no remaining cancer at surgery after a six-week regimen of botensilimab and balstilimab. The investigator-initiated study was sponsored by the Netherlands Cancer Institute. Agenus is expanding the study to a dMMR rectal cancer organ-preservation cohort and continuing to investigate the treatment in MSS colon cancer. https://openbell.ai/news/SGRY:1792976617000 2026-10-26T01:03:37.000Z daily 0.9 https://cdn.brandfetch.io/SGRY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bon Secours Mercy Health Reportedly Nears $6 Billion Acquisition of Surgery Partners Bon Secours Mercy Health is reportedly nearing an estimated $6 billion acquisition of Surgery Partners, which operates a national network of ambulatory surgery centers and surgical hospitals. The deal is still in progress and would require finalization and regulatory approval; no transaction structure or timeline was disclosed. If completed, it would mark a significant consolidation in healthcare services. https://openbell.ai/news/NVDA:1792974658031 2026-10-26T00:30:58.031Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $NVDA - **SpaceX’s $40 billion AI-chip purchase:** Bullish; highlights massive AI infrastructure spending, with commenters asking who will supply the chips. - **South Korea’s Q2 current-account surplus:** Bullish; its reported surplus-to-GDP ratio drew attention as unusually high. - **Daily investing discussion:** Neutral; general market discussion and advice. https://openbell.ai/news/BBD:1792972949000 2026-10-26T00:02:29.000Z daily 0.9 https://cdn.brandfetch.io/BBD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Banco Bradesco S.A. Reports Q3 2026 Financial Results Banco Bradesco reported resilient profit levels in Q3 2026 and 11.1% growth in its loan portfolio. The bank also disclosed a R$10 billion capital boost. The report did not provide specific profit or revenue figures or describe a stock-price impact. https://openbell.ai/news/BORR:1792962105000 2026-10-25T21:01:45.000Z daily 0.9 https://cdn.brandfetch.io/BORR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Borr Drilling Confirms Prospector 5 Rig Incident Offshore Gabon Borr Drilling confirmed that its Prospector 5 rig sank offshore Gabon on October 24, 2026, after a “punch through” during preload activities caused it to lose stability. Of the 115 people aboard, 110 have been accounted for and five remain missing. Borr activated its emergency response team and is coordinating search-and-rescue efforts with local authorities and customer BW Energy. https://openbell.ai/news/VITR:1792958527000 2026-10-25T20:02:07.000Z daily 0.9 https://cdn.brandfetch.io/VITR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vitrolife AB: Interim report Q3, 2026 Vitrolife AB reported Q3 2026 sales of SEK 884 million, up from SEK 835 million a year earlier. Organic growth was 6% in local currencies, excluding the exited NACE and GPDx product lines; total growth was 4% in local currencies and 6% in SEK. Growth was primarily driven by the Technologies segment. https://openbell.ai/news/XIOR:1792958511000 2026-10-25T20:01:51.000Z daily 0.9 https://cdn.brandfetch.io/XIOR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Xior Reports Strong Nine-Month Results and Confirms 2026 Outlook Xior Student Housing reported nine-month 2026 EPRA profit of €74.02 million, up 6% year over year, and earnings per share of €1.59. Occupancy reached 98.5%, while like-for-like rental growth was 4.62%, which the company described as its strongest rental season on record. Xior reaffirmed its 2026 targets of €2.30 EPRA profit per share and a €1.84 dividend per share, up 4%. It also secured a new €100 million USPP and expects its debt ratio, currently slightly above 50%, to fall below that level by year-end. https://openbell.ai/news/BMY:1792933310000 2026-10-25T13:01:50.000Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Data for Pumitamig in Advanced NSCLC BioNTech and Bristol Myers Squibb reported initial Phase 2 ROSETTA Lung-107 results for pumitamig plus docetaxel in metastatic NSCLC that progressed after first-line immunotherapy and chemotherapy. The combination achieved a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months, with a manageable safety profile and no new safety signals. The companies said the findings support continued development of pumitamig; the article did not report financial results or stock-price movements. https://openbell.ai/news/AMZN:1792931451735 2026-10-25T12:30:51.735Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $AMZN **Sentiment: Neutral.** Amazon’s reported $220 billion AI spending and capacity constraints signal strong demand, but investors are wary that AI customers may lack funding to sustain spending amid broader market uncertainty. https://openbell.ai/news/EPEN:1792915382000 2026-10-25T08:03:02.000Z daily 0.9 https://cdn.brandfetch.io/EPEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ependion Reports Q3 Results with Firm Growth and Record EBITA Ependion AB reported firm growth in the third quarter of 2026, with EBITA reaching a record high. The company said results reflected performance in its industrial automation and data communication businesses; the article provided no specific revenue or profit figures. https://openbell.ai/news/LINDEX:1792911701000 2026-10-25T07:01:41.000Z daily 0.9 https://cdn.brandfetch.io/LINDEX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lindex Group Reports Q3 2026 Financial Results Lindex Group reported third-quarter 2026 revenue of €243.5 million, up from €227.6 million a year earlier. Adjusted operating profit was €24.1 million, with an adjusted operating margin of 10%; gross margin was 60.1%. The results cover the three months ending in 2026. https://openbell.ai/news/EGO:1792890448000 2026-10-25T01:07:28.000Z daily 0.9 https://cdn.brandfetch.io/EGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Upgrades Eldorado Gold to Buy Canaccord Genuity has upgraded Eldorado Gold Corporation from a Hold to a Buy rating, reflecting an improved outlook on the company's market position. The firm has set a price target of CA$57 for Eldorado's shares, indicating confidence in the company's performance potential. https://openbell.ai/news/CF:1792890448000 2026-10-25T01:07:28.000Z daily 0.9 https://cdn.brandfetch.io/CF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Reaffirms Buy Rating on Compass Therapeutics Canaccord Genuity has reaffirmed its Buy rating on Compass Therapeutics (Ticker: CF) after positive results from the Phase 2/3 COMPANION-002 study of tovecimig for advanced biliary tract cancer. The study met its primary and key secondary endpoints, which has influenced Canaccord Genuity's continued support based on the clinical data and the company's development progress. https://openbell.ai/news/EH:1792890261000 2026-10-25T01:04:21.000Z daily 0.9 https://cdn.brandfetch.io/EH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shenzhen Bao'an District and EHang Launch UAM Operation Demonstration Center at OH Bay EHang Holdings Limited has launched a UAM Operation Demonstration Center at OH Bay in Shenzhen's Bao'an District, in collaboration with the local government. The center aims to demonstrate autonomous aerial vehicle operations, highlighted by a demonstration flight of the EH216-S pilotless eVTOL aircraft. This initiative is part of EHang's efforts to advance urban air mobility infrastructure. https://openbell.ai/news/DGICA:1792890250000 2026-10-25T01:04:10.000Z daily 0.9 https://cdn.brandfetch.io/DGICA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Donegal Insurance Expands Partnership with ZestyAI for AI-Powered Property Risk Assessment Donegal Insurance Group is expanding its partnership with ZestyAI to enhance property risk assessments through AI technology. This collaboration aims to improve Donegal's underwriting processes and risk evaluation capabilities. The initiative is part of Donegal's strategy to modernize operations and offer more precise insurance solutions to policyholders. https://openbell.ai/news/SRTA:1792890232000 2026-10-25T01:03:52.000Z daily 0.9 https://cdn.brandfetch.io/SRTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Third Point Files 13D Activist Stake in Strata Critical Medical Third Point has transitioned from a passive 13G filing to an activist 13D position regarding its investment in Strata Critical Medical (SRTA). The firm acquired 170,011 shares between August 31 and October 13, 2026, at prices between $4.53 and $5.66, while selling 43,500 shares in the same timeframe. Third Point believes that SRTA's stock is undervalued and sees potential in the company's business. https://openbell.ai/news/RCBC:1792890228000 2026-10-25T01:03:48.000Z daily 0.9 https://cdn.brandfetch.io/RCBC/w/400/h/400?c=1idopYfmtR7ZKg8QMud River City Bank Announces Quarterly Cash Dividend River City Bank has announced a quarterly cash dividend on its common stock, which will be paid to shareholders on November 17, 2026. This announcement coincides with the bank's third-quarter financial results, highlighting growth in net income and core operating performance for the period. https://openbell.ai/news/UMAC:1792890227000 2026-10-25T01:03:47.000Z daily 0.9 https://cdn.brandfetch.io/UMAC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Northland Securities Initiates Coverage of Unusual Machines with Buy Rating Northland Securities has begun coverage of Unusual Machines, Inc. (UMAC) with a buy rating, indicating a positive outlook on the company. Analyst Michael Latimore has set a price target of $30 for UMAC's stock, reflecting confidence in its position within the drone and drone component market. https://openbell.ai/news/CLYM:1792890225000 2026-10-25T01:03:45.000Z daily 0.9 https://cdn.brandfetch.io/CLYM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Climb Bio Presents Initial PrisMN Phase 2 Data for Budoprutug at ASN Kidney Week 2026 Climb Bio, Inc. presented initial data from its PrisMN Phase 2 study of budoprutug at ASN Kidney Week 2026, showing that a low dose of 200 mg achieved B-cell depletion and a reduction in PLA2R antibodies at 12 weeks. These results align with prior Phase 1b data for the monoclonal antibody therapy aimed at treating immune-mediated diseases. https://openbell.ai/news/MOON:1792890224000 2026-10-25T01:03:44.000Z daily 0.9 https://cdn.brandfetch.io/MOON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Scotiabank Maintains Blue Moon Metals with Buy Rating and Raises Target Price Scotiabank analyst Eric Winmill has maintained a 'Buy' rating for Blue Moon Metals (BMM) and raised the price target from $9.99 to $10. This adjustment indicates a continued positive outlook on the company's performance and market position, as reported by independent third-party TipRanks. https://openbell.ai/news/ARDX:1792890214000 2026-10-25T01:03:34.000Z daily 0.9 https://cdn.brandfetch.io/ARDX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ardelyx Presents Real-World Data at ASN Kidney Week 2026 for XPHOZAH At ASN Kidney Week 2026, Ardelyx presented real-world data on XPHOZAH (tenapanor) showing that serum phosphate levels decreased in dialysis patients over six months, with adjusted mean reductions between 0.80 and 1.55 mg/dL. The company also discussed the challenges of managing hyperphosphatemia and its associated health risks. These findings support the clinical utility of XPHOZAH in improving phosphate control in patients.